Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.01.2014 | original article | Ausgabe 1-2/2014

Wiener klinische Wochenschrift 1-2/2014

Long-term follow-up after allogeneic stem cell transplantation in patients with myelodysplastic syndromes or secondary acute myeloid leukemia: a single center experience

Wiener klinische Wochenschrift > Ausgabe 1-2/2014
Alexandra Boehm, Wolfgang R. Sperr, Peter Kalhs, Hildegard Greinix, Peter Valent, Nina Worel, Alexander Kainz, Margit Mitterbauer, Marija Bojic, MD Werner Rabitsch


Objective and methods

We performed a single center analysis of 60 adult patients (33 males and 27 females) with myelodysplastic syndromes (MDS) or secondary acute myeloid leukemia (AML) who underwent allogeneic hematopoietic stem cell transplantation (HCT) at our institution.


Allogeneic stem cell in patients were transplanted between 1988 and 2010, 28 had an human leukocyte antigen (HLA)-identical sibling donor, 23 had an HLA-identical unrelated donor, and 9 had an 1 allele mismatched donor. The median age at time of HCT was 44 (range: 18–68) years. Conditioning therapy was myeloablative in 36 patients and consisted of a reduced-intensity conditioning (RIC) regimen in 24 patients. Graft-versus-host disease (GvHD) prophylaxis was performed with a combination of methotrexate and cyclosporine A in 36 patients, and cyclosporine A plus mycophenolate mofetil in 24 patients. The 10-year probability of overall survival was 46 %.


In a multivariate analysis, we identified pretransplantation serum ferritin as the only independent adverse prognostic variable predicting survival in our patients.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 1-2/2014

Wiener klinische Wochenschrift 1-2/2014 Zur Ausgabe

MUW researcher of the month

Researcher of the Month